Biotech Values

[rkrw]

A premium price to telapravir is not going to happen.

I do think a great number of oral products in early development will be dropped because they're too far behind and will be too expensive and risky to justify the investment. If that's what you mean by group think. How that relates to lambda's future role i'm not sure.

I'll rephrase it for you again, to my mind it's a lot of money for bristol to pay, upfront, milestones, development costs, royalties for a 70% chance (your estimate) it will be obsoleted. I'd like to know what Roche or SGP bid for the program if at all. I think there would be better places for bristol to invest over $1B.